Tag: adeno associated virus vectors in gene therapy market key players

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?

The adeno-associated virus (avv) vectors in gene therapy market size has seen rapid growth recently. It is projected to increase from $3.16 billion in 2025 to $3.7 billion in 2026, at a compound annual growth rate (CAGR) of 17.3%. This historical expansion is attributable to several key factors, including advancements in viral vector safety, increased research into rare genetic disorders, successful outcomes in clinical gene therapy, a rise in regulatory approvals, and substantial investments in academic research.

The adeno-associated virus (avv) vectors in gene therapy market is anticipated to experience significant expansion over the next few years. Its valuation is projected to reach $6.99 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 17.2%. This growth during the forecast period can be attributed to the launch of commercial gene therapies, the demand for scalable vector production, the expansion of precision medicine, incentives for orphan drugs, and an increase in global clinical trials. Major trends expected within this period include the broadening of gene augmentation therapies, a rising need for gene treatments for rare diseases, the development of in vivo gene delivery, a surge in commercial-scale vector manufacturing, and a focus on long-term therapeutic durability.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Growth Backed By Core Demand Fundamentals

The increasing emphasis on gene-based therapies is projected to boost the adeno-associated virus (AAV) vectors within the gene therapy market going forward. Gene-based therapies are treatments designed to modify or manipulate genes to prevent, treat, or cure diseases at the molecular level. Progress in genetic research is fueling the intensified focus on developing gene-based therapies, as these advancements improve the precision and effectiveness of gene editing techniques. Adeno-associated virus (AAV) vectors in gene therapy assist in creating gene-based therapies by delivering therapeutic genes safely and efficiently into target cells, attributable to their low immunogenicity and ability to provide long-term gene expression. For instance, in 2023, according to IQVIA, a US-based provider of advanced analytics and technology solutions for the life sciences industry, global spending on cell and gene therapies amounted to $5.9 billion, representing a 38% increase from 2022. Consequently, the growing focus on creating gene-based therapies is driving the expansion of the adeno-associated virus (AAV) vectors market.

Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Segment Trends And Revenue Contributors

The adeno-associated virus (avv) vectors in gene therapy market covered in this report is segmented –

1) By Type of Therapy: Gene Augmentation, Immunotherapy, Other Type of Therapy

2) By Type of Gene Delivery Method Used: Ex Vivo, In Vivo

3) By Scale of Operation: Preclinical, Clinical, Commercial

4) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Area

Subsegments:

1) By Gene Augmentation: Monogenic Disorders, Neurological Disorders, Muscular Disorders, Ophthalmological Disorders, Metabolic Disorders

2) By Immunotherapy: Oncology, Infectious Diseases, Autoimmune Disorders, Vaccine Development, T-Cell Engineering

3) By Other Type of Therapy: Gene Editing Support, RNA Interference, Neuroprotection and Neuroregeneration, Anti-Inflammatory Applications, Regenerative Medicine

Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Growth Trends Reshaping The Competitive Landscape

Leading companies in the adeno-associated virus (AAV) vectors in the gene therapy market are concentrating on advanced innovations, such as tailored vector diversity for assay versatility, to improve target tissue specificity, enhance therapeutic effectiveness, and accelerate the creation of personalized gene therapies across various indications. Tailored vector diversity for assay versatility involves employing multiple AAV serotypes or constructs to support diverse analytical tests and therapeutic applications. For instance, in May 2024, Charles River Laboratories, a US-based pharmaceutical company, unveiled new reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV), designed to meet the expanding demands of cell and gene therapy (CGT) development. This portfolio aims to facilitate a smoother progression from early-stage research to GMP-grade production, aiding in standardizing processes and enhancing consistency in viral vector manufacturing. This introduction directly addresses a primary challenge in advancing CGT programs towards clinical and commercial readiness.

Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Competitive Landscape: Which Companies Lead The Industry?

Major companies operating in the adeno-associated virus (avv) vectors in gene therapy market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Astellas Gene Therapies Inc., Biogen Inc., Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc.

View The Full Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/adeno-associated-virus-avv-vectors-in-gene-therapy-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Regional Distribution: Which Areas Power Market Growth?

North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2025. The regions covered in the adeno-associated virus (avv) vectors in gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Forecast Highlighting Growth From $3.7 Billion To $6.98 Billion

The market for adeno-associated virus (AAV) vectors in gene therapy has experienced rapid expansion in recent years. Projected to increase from $3.16 billion in 2025 to $3.7 billion in 2026, this growth reflects a compound annual growth rate (CAGR) of 17.3%. Historical expansion has been driven by progress in viral vector safety, research into rare genetic disorders, successful clinical gene therapy outcomes, regulatory approvals, and investments in academic research.

The market for adeno-associated virus (AAV) vectors in gene therapy is anticipated to experience substantial expansion over the coming years. By 2030, its valuation is projected to reach $6.99 billion, reflecting a compound annual growth rate (CAGR) of 17.2%. This forecasted growth is driven by factors such as the commercialization of gene therapies, rising needs for scalable vector production, the advancement of precision medicine, incentives for orphan drugs, and an increase in global clinical trials. Key trends shaping this period include the broadening of gene augmentation therapies, heightened interest in treatments for rare genetic diseases, the progress of in vivo gene delivery techniques, the scale-up of commercial vector production, and an emphasis on ensuring long-term therapeutic durability.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Demand Drivers: What Is Fueling Industry Growth?

The anticipated expansion of the adeno-associated virus (AAV) vectors market within the gene therapy sector is being driven by a growing emphasis on gene-based treatments. These therapies involve modifying or manipulating genes at the molecular level to prevent, treat, or cure diseases. Progress in genetic research is fueling this heightened focus, as it improves the accuracy and efficacy of gene editing methods. AAV vectors play a crucial role in developing such therapies by safely and efficiently delivering therapeutic genes to target cells, thanks to their low immunogenicity and capacity for sustained gene expression. For example, IQVIA, a US-based provider of advanced analytics and technology solutions for the life sciences industry, reported that global spending on cell and gene therapies hit $5.9 billion in 2023, marking a 38% rise from 2022. Consequently, the rising focus on creating gene-based therapies is propelling the growth of the AAV vectors market.

Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Segmentation: How Is The Market Structured Across Key Categories?

The adeno-associated virus (avv) vectors in gene therapy market covered in this report is segmented –

1) By Type of Therapy: Gene Augmentation, Immunotherapy, Other Type of Therapy

2) By Type of Gene Delivery Method Used: Ex Vivo, In Vivo

3) By Scale of Operation: Preclinical, Clinical, Commercial

4) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Area

Subsegments:

1) By Gene Augmentation: Monogenic Disorders, Neurological Disorders, Muscular Disorders, Ophthalmological Disorders, Metabolic Disorders

2) By Immunotherapy: Oncology, Infectious Diseases, Autoimmune Disorders, Vaccine Development, T-Cell Engineering

3) By Other Type of Therapy: Gene Editing Support, RNA Interference, Neuroprotection and Neuroregeneration, Anti-Inflammatory Applications, Regenerative Medicine

Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Innovation Trends: Which Developments Are Transforming The Industry?

Leading firms active in the adeno-associated virus (AAV) vector segment of the gene therapy market are concentrating their efforts on cutting-edge innovation, particularly customized vector diversity for assay flexibility, aiming to boost target tissue specificity, enhance therapeutic efficacy, and speed up development of tailored gene therapies across a range of indications. This concept involves employing different AAV serotypes or constructs to facilitate a variety of analytical tests and therapeutic uses. As an example, Charles River Laboratories, a pharmaceutical company headquartered in the United States, launched novel reference materials for AAV and lentiviral vectors (LVV) in May 2024. Designed to meet the expanding requirements of cell and gene therapy (CGT) development, these materials enable a more seamless shift from initial research stages to GMP-grade manufacturing. The portfolio contributes to process standardization and enhanced consistency in producing viral vectors. This introduction tackles a critical obstacle in scaling CGT programs for clinical and commercial application.

Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Competitive Landscape And Leading Companies

Major companies operating in the adeno-associated virus (avv) vectors in gene therapy market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Astellas Gene Therapies Inc., Biogen Inc., Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc.

Access The Complete Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/adeno-associated-virus-avv-vectors-in-gene-therapy-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Geographic Landscape: Which Region Dominates Industry Growth?

North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2025. The regions covered in the adeno-associated virus (avv) vectors in gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Change Between 2026 And 2030?

The adeno-associated virus (avv) vectors in gene therapy market size has demonstrated rapid expansion in recent years. This market is forecasted to grow from $3.16 billion in 2025 to $3.7 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.3%. The historical increase in market size can be attributed to developments in viral vector safety, enhanced research into rare genetic disorders, successful clinical gene therapy applications, various regulatory approvals, and sustained investments in academic research.

The adeno-associated virus (avv) vectors in gene therapy market is anticipated to witness significant expansion in the coming years. It will grow to $6.99 billion in 2030 at a compound annual growth rate (CAGR) of 17.2%. This expansion during the projected timeframe is driven by factors such as the introduction of commercial gene therapies, the need for scalable vector production, the proliferation of precision medicine, encouragement from orphan drug incentives, and an increase in global clinical trials. Notable trends for the forecast period feature the expansion of gene augmentation therapies, increasing demand for rare disease gene treatments, the growing adoption of in vivo gene delivery, enhanced commercial-scale vector manufacturing, and a concentrated effort on achieving long-term therapeutic durability.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp

What Influential Factors Are Boosting The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Demand?

The increasing emphasis on gene-based therapies is anticipated to stimulate the expansion of adeno-associated virus (AAV) vectors within the gene therapy market. Gene-based therapies involve medical interventions that alter or manipulate genes to combat, manage, or cure illnesses at a molecular level. Progress in genetic research underpins this growing focus, as such advancements enhance the precision and efficacy of gene editing methods. Adeno-associated virus (AAV) vectors in gene therapy facilitate the creation of gene-based therapies by ensuring the secure and efficient delivery of therapeutic genes into target cells, primarily due to their low immunogenicity and capacity for sustained gene expression. As an illustration, in 2023, IQVIA, a US-based provider of advanced analytics and technology solutions for the life sciences industry, reported that global spending on cell and gene therapies reached $5.9 billion, marking a 38% increase from 2022. Consequently, the heightened focus on developing gene-based therapies is propelling the growth of the adeno-associated virus (AAV) vectors market.

What Are The Major Segment Categories Within The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

The adeno-associated virus (avv) vectors in gene therapy market covered in this report is segmented –

1) By Type of Therapy: Gene Augmentation, Immunotherapy, Other Type of Therapy

2) By Type of Gene Delivery Method Used: Ex Vivo, In Vivo

3) By Scale of Operation: Preclinical, Clinical, Commercial

4) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Area

Subsegments:

1) By Gene Augmentation: Monogenic Disorders, Neurological Disorders, Muscular Disorders, Ophthalmological Disorders, Metabolic Disorders

2) By Immunotherapy: Oncology, Infectious Diseases, Autoimmune Disorders, Vaccine Development, T-Cell Engineering

3) By Other Type of Therapy: Gene Editing Support, RNA Interference, Neuroprotection and Neuroregeneration, Anti-Inflammatory Applications, Regenerative Medicine

What Trends Are Influencing The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

Companies operating within the adeno-associated virus (AAV) vectors in the gene therapy market are concentrating on advanced innovations, such as the adaptation of vector diversity for assay versatility. This strategic focus is intended to improve target tissue specificity, heighten therapeutic efficacy, and expedite the creation of customized gene therapies for a broad spectrum of indications. Tailored vector diversity for assay versatility signifies the utilization of multiple AAV serotypes or constructs to support a variety of analytical tests and therapeutic applications. Illustratively, in May 2024, Charles River Laboratories, a US-based pharmaceutical company, launched novel reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV). These materials are designed to cater to the expanding requirements of cell and gene therapy (CGT) development. The portfolio aids in ensuring a smoother transition from early-stage research to GMP-grade production, contributing to process standardization and improved consistency in viral vector manufacturing. This introduction directly addresses a critical challenge in advancing CGT programs towards successful clinical and commercial implementation.

Who Are The Firms Contributing To The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Ecosystem?

Major companies operating in the adeno-associated virus (avv) vectors in gene therapy market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Astellas Gene Therapies Inc., Biogen Inc., Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc.

Access The Complete Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/adeno-associated-virus-avv-vectors-in-gene-therapy-global-market-report

Which Region Commands The Largest Share Of The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2025. The regions covered in the adeno-associated virus (avv) vectors in gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp

Browse Through More Reports Similar to the Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market 2026, By The Business Research Company

Adeno Associated Viral Vectors Market Report 2026

https://www.thebusinessresearchcompany.com/report/adeno-associated-viral-vectors-global-market-report

Nucleic Acid Based Gene Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Over The 2026–2030 Period?

The adeno-associated virus (avv) vectors in gene therapy market has experienced substantial expansion in recent years. This market is projected to grow from $3.16 billion in 2025 to $3.7 billion in 2026, registering a compound annual growth rate (CAGR) of 17.3%. Historically, this growth can be attributed to advances in viral vector safety, increased research into rare genetic disorders, successful clinical gene therapy outcomes, a rise in regulatory approvals, and considerable investments in academic research.

The adeno-associated virus (avv) vectors in gene therapy market is projected for substantial expansion over the coming years, expected to attain a valuation of $6.99 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 17.2%. This projected increase can be attributed to factors such as the introduction of commercial gene therapies, the demand for scalable vector production, the growth of precision medicine, incentives for orphan drugs, and an uptick in global clinical trials. Notable developments anticipated during this timeframe encompass the proliferation of gene augmentation therapies, a rising need for gene treatments for rare diseases, advancements in in vivo gene delivery, augmented commercial-scale vector manufacturing, and a concentrated effort on ensuring long-term therapeutic durability.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp

Which Primary Drivers Are Impacting The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Growth?

The escalating emphasis on gene-based therapies is anticipated to drive the expansion of adeno-associated virus (AAV) vectors within the gene therapy market moving forward. Gene-based therapies are treatments designed to modify or manipulate genes for the prevention, treatment, or cure of diseases at a molecular level. Progress in genetic research underpins this growing focus on developing gene-based therapies, as it enhances the precision and effectiveness of gene editing techniques. Adeno-associated virus (AAV) vectors in gene therapy facilitate the creation of gene-based therapies by safely and efficiently delivering therapeutic genes into target cells, due to their low immunogenicity and capacity for long-term gene expression. Illustratively, in 2023, global spending on cell and gene therapies reached $5.9 billion, a 38% increase from 2022, as reported by IQVIA, a US-based provider of advanced analytics and technology solutions for the life sciences industry. Thus, the increasing focus on gene-based therapies is propelling the growth of the adeno-associated virus (AAV) vectors market.

What Segment Categories Shape The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Segment Landscape?

The adeno-associated virus (avv) vectors in gene therapy market covered in this report is segmented –

1) By Type of Therapy: Gene Augmentation, Immunotherapy, Other Type of Therapy

2) By Type of Gene Delivery Method Used: Ex Vivo, In Vivo

3) By Scale of Operation: Preclinical, Clinical, Commercial

4) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Area

Subsegments:

1) By Gene Augmentation: Monogenic Disorders, Neurological Disorders, Muscular Disorders, Ophthalmological Disorders, Metabolic Disorders

2) By Immunotherapy: Oncology, Infectious Diseases, Autoimmune Disorders, Vaccine Development, T-Cell Engineering

3) By Other Type of Therapy: Gene Editing Support, RNA Interference, Neuroprotection and Neuroregeneration, Anti-Inflammatory Applications, Regenerative Medicine

Which Trends Are Shaping Growth In The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

Major companies engaged in the adeno-associated virus (AAV) vectors in the gene therapy market are dedicating efforts to advanced innovation, such as developing tailored vector diversity for assay versatility. This strategy aims to enhance target tissue specificity, improve therapeutic efficacy, and accelerate the progression of customized gene therapies for a range of indications. Tailored vector diversity for assay versatility refers to the utilization of multiple AAV serotypes or constructs to support diverse analytical tests and therapeutic applications. As an example, in May 2024, Charles River Laboratories, a US-based pharmaceutical company, introduced new reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV). These materials are intended to support the expanding requirements of cell and gene therapy (CGT) development. The portfolio facilitates a smoother transition from early-stage research to GMP-grade production, contributing to the standardization of processes and improved consistency in viral vector manufacturing. This launch directly addresses a critical challenge in scaling CGT programs toward achieving clinical and commercial readiness.

Who Are The Companies Operating Across The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Value Chain?

Major companies operating in the adeno-associated virus (avv) vectors in gene therapy market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Astellas Gene Therapies Inc., Biogen Inc., Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc.

Get The Full Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/adeno-associated-virus-avv-vectors-in-gene-therapy-global-market-report

Which Region Leads The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market In Terms Of Market Share?

North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2025. The regions covered in the adeno-associated virus (avv) vectors in gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/adeno-associated-virus-avv-vectors-in-gene-therapy-global-market-report

Browse Through More Reports Similar to the Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market 2026, By The Business Research Company

Adeno Associated Viral Vectors Market Report 2026

https://www.thebusinessresearchcompany.com/report/adeno-associated-viral-vectors-global-market-report

Nucleic Acid Based Gene Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the adeno-associated virus (avv) vectors in gene therapy market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market in 2026, and what figure is it projected to hit by 2030?

The adeno-associated virus (avv) vectors in gene therapy market has experienced swift expansion in recent years. It is projected to increase from $3.16 billion in 2025 to $3.7 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.3%. The market’s past growth is attributable to advancements in viral vector safety, research into rare genetic disorders, successful clinical gene therapy outcomes, regulatory approvals, and significant academic research investments.

The adeno-associated virus (avv) vectors in gene therapy market is projected to experience swift expansion over the coming years, with its size forecast to reach $6.99 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 17.2%. Factors driving this growth during the projection period include the introduction of commercial gene therapies, the increasing need for scalable vector production, the expansion of precision medicine, incentives for orphan drugs, and the rise in global clinical trials. Key trends anticipated for the forecast period encompass the broadening of gene augmentation therapies, a surge in demand for gene treatments targeting rare diseases, advancements in in vivo gene delivery, an increase in commercial-scale vector manufacturing, and an emphasis on achieving sustained therapeutic effectiveness.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp

Which Drivers Are Affecting Market Participation In The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

A growing emphasis on gene-based treatments is anticipated to drive the expansion of adeno-associated virus (AAV) vectors within the gene therapy market moving ahead. These therapies involve modifying or manipulating genes to address, prevent, or cure illnesses at a molecular level. Progress in genetic research fuels this intensified focus on developing gene-based treatments, given their ability to improve the accuracy and efficacy of gene editing methods. Adeno-associated virus (AAV) vectors play a crucial role in gene therapy by facilitating the creation of gene-based therapies; they safely and effectively transport therapeutic genes into specific cells due to their minimal immune response and capacity for sustained gene expression. For example, in 2023, data from IQVIA, a US-based provider of advanced analytics and technology solutions for the life sciences industry, indicated that worldwide expenditure on cell and gene therapies hit $5.9 billion, signifying a 38% rise compared to 2022. Consequently, the heightened emphasis on developing gene-based therapies is propelling the expansion of the adeno-associated virus (AAV) vectors market.

What Segment Categories Are Covered In The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

The adeno-associated virus (avv) vectors in gene therapy market covered in this report is segmented –

1) By Type of Therapy: Gene Augmentation, Immunotherapy, Other Type of Therapy

2) By Type of Gene Delivery Method Used: Ex Vivo, In Vivo

3) By Scale of Operation: Preclinical, Clinical, Commercial

4) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Area

Subsegments:

1) By Gene Augmentation: Monogenic Disorders, Neurological Disorders, Muscular Disorders, Ophthalmological Disorders, Metabolic Disorders

2) By Immunotherapy: Oncology, Infectious Diseases, Autoimmune Disorders, Vaccine Development, T-Cell Engineering

3) By Other Type of Therapy: Gene Editing Support, RNA Interference, Neuroprotection and Neuroregeneration, Anti-Inflammatory Applications, Regenerative Medicine

What Trends Are Projected To Support The Growth Of The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

Major companies operating in the adeno-associated virus (AAV) vectors in the gene therapy market are focusing on advanced innovation, such as tailored vector diversity for assay versatility, to enhance target tissue specificity, improve therapeutic efficacy, and accelerate the development of customized gene therapies across various indications. Tailored vector diversity for assay versatility refers to utilizing multiple AAV serotypes or constructs to support various analytical tests and therapeutic applications. For instance, in May 2024, Charles River Laboratories, a US-based pharmaceutical company, introduced new reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV). These materials are intended to support the growing needs of cell and gene therapy (CGT) development. The portfolio facilitates a smoother transition from early-stage research to GMP-grade production. It helps standardize processes and improve consistency in viral vector manufacturing. This launch addresses a key challenge in scaling CGT programs toward clinical and commercial readiness.

Which Major Industry Participants Are Leading The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Growth?

Major companies operating in the adeno-associated virus (avv) vectors in gene therapy market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Astellas Gene Therapies Inc., Biogen Inc., Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/adeno-associated-virus-avv-vectors-in-gene-therapy-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2025. The regions covered in the adeno-associated virus (avv) vectors in gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24135&type=smp

Browse Through More Reports Similar to the Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market 2026, By The Business Research Company

Adeno Associated Viral Vectors Market Report 2026

https://www.thebusinessresearchcompany.com/report/adeno-associated-viral-vectors-global-market-report

Nucleic Acid Based Gene Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the adeno-associated virus (avv) vectors in gene therapy market from 2025–2034 with trusted insights from The Business Research Company

What CAGR And Valuation Are Anticipated For The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market By The End Of 2029?

The adeno-associated virus (avv) vectors in gene therapy market has experienced substantial growth in recent times. It is set to increase from $2.7 billion in 2024 to $3.16 billion in 2025, achieving a compound annual growth rate (CAGR) of 16.7%. Historically, this expansion has been driven by factors such as greater investment in gene therapy research, the growing embrace of gene editing technologies, an uptick in genetic disorders and unaddressed medical requirements, escalating demand for specific targeted therapies, and enhanced cooperation between biotech firms and research institutions.

The adeno-associated virus (AVV) vectors in gene therapy market is anticipated to experience substantial growth in the upcoming years. It is projected to climb to $6.09 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 17.6%. This expansion during the forecast period is driven by advancements in AAV capsid engineering, a heightened focus on precision medicine, increased investment in genetic research and biotechnology, a rise in gene therapy clinical trials and approvals, and growing demand for personalized treatments. Noteworthy trends for the forecast period include progress in artificial intelligence applications for AAV capsid engineering, the development of hybrid AAV vectors capable of carrying larger genetic payloads, innovations in bispecific antibody-mediated AAV targeting, improvements in scalable AAV production and purification technologies, and the creation of flexible AAV platforms supporting various viral vectors.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp

Which Business Drivers Are Underpinning The Growth Of The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

A rising emphasis on gene-based treatments is anticipated to drive the expansion of adeno-associated virus (AAV) vectors within the gene therapy market moving ahead. Gene-based therapies are medical interventions that alter or manipulate genes to prevent, treat, or cure diseases at the molecular level. Advancements in genetic research are fueling this increasing focus on creating such therapies, as they enhance the precision and effectiveness of gene editing techniques. Adeno-associated virus (AAV) vectors in gene therapy facilitate the development of gene-based therapies by safely and efficiently delivering therapeutic genes into target cells, due to their low immunogenicity and ability to provide long-term gene expression. For example, in 2023, according to IQVIA, a US-based provider of advanced analytics and technology solutions for the life sciences industry, global spending on cell and gene therapies reached $5.9 billion, representing a 38% increase from 2022. Therefore, the increasing focus on developing gene-based therapies is propelling the growth of the adeno-associated virus (AAV) vectors market.

What Are The Principal Segment Types In The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

The adeno-associated virus (avv) vectors in gene therapy market covered in this report is segmented –

1) By Type of Therapy: Gene Augmentation, Immunotherapy, Other Type of Therapy

2) By Type of Gene Delivery Method Used: Ex Vivo, In Vivo

3) By Scale of Operation: Preclinical, Clinical, Commercial

4) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Area

Subsegments:

1) By Gene Augmentation: Monogenic Disorders, Neurological Disorders, Muscular Disorders, Ophthalmological Disorders, Metabolic Disorders

2) By Immunotherapy: Oncology, Infectious Diseases, Autoimmune Disorders, Vaccine Development, T-Cell Engineering

3) By Other Type of Therapy: Gene Editing Support, RNA Interference, Neuroprotection and Neuroregeneration, Anti-Inflammatory Applications, Regenerative Medicine

How Are Industry Trends Steering The Expansion Of The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

Major companies operating in the adeno-associated virus (AAV) vectors in the gene therapy market are prioritizing sophisticated innovation, such as tailored vector diversity for assay versatility, to enhance target tissue specificity, improve therapeutic efficacy, and expedite the development of customized gene therapies across various indications. Tailored vector diversity for assay versatility refers to employing multiple AAV serotypes or constructs to facilitate various analytical tests and therapeutic applications. As an illustration, in May 2024, Charles River Laboratories, a US-based pharmaceutical company, launched new reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV). These materials are intended to support the expanding requirements of cell and gene therapy (CGT) development. The portfolio aims to enable a smoother progression from early-stage research to GMP-grade production, contributing to the standardization of processes and the improvement of consistency in viral vector manufacturing. This introduction addresses a significant challenge in advancing CGT programs toward clinical and commercial readiness.

Which Companies Are Contributing Significantly To The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Growth?

Major companies operating in the adeno-associated virus (AVV) vectors in gene therapy market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Astellas Gene Therapies Inc., Biogen Inc., Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/adeno-associated-virus-avv-vectors-in-gene-therapy-global-market-report

Which Region Offers The Most Opportunity For Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Expansion?

North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2024. The regions covered in the adeno-associated virus (AVV) vectors in gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=24135&type=smp

Browse Through More Reports Similar to the Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market 2025, By The Business Research Company

Gene Editing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report

Nucleic Acid Based Gene Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Genes Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Future Market Size Estimation For The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Covering 2025–2034?

The adeno-associated virus (avv) vectors in gene therapy market has witnessed rapid growth in recent years. It is anticipated to increase from $2.7 billion in 2024 to $3.16 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 16.7%. This historical expansion can be attributed to augmented investment in gene therapy research, the growing embrace of gene editing technologies, a surge in genetic disorders and unaddressed medical requirements, heightened demand for targeted therapies, and an uptick in collaborations between biotechnology companies and research institutions.

The adeno-associated virus (AVV) vectors in gene therapy market size is projected for substantial expansion in the coming years, reaching $6.09 billion by 2029 with a compound annual growth rate (CAGR) of 17.6%. This anticipated growth is driven by rising advancements in AAV capsid engineering, an increasing focus on precision medicine, growing investment in genetic research and biotechnology, a rise in gene therapy clinical trials and approvals, and increasing demand for personalized treatments. Major trends foreseen for this period include advancements in artificial intelligence applied to AAV capsid engineering, the development of hybrid AAV vectors designed for larger genetic payloads, innovation in bispecific antibody-mediated AAV targeting, progress in scalable AAV production and purification technologies, and the creation of flexible AAV platforms that support diverse viral vectors.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Industry?

A growing emphasis on gene-based therapies is anticipated to drive the expansion of adeno-associated virus (AAV) vectors within the gene therapy market in the future. Such therapies involve modifying or manipulating genes to address, treat, or prevent diseases at a molecular level. Progress in genetic research fuels this heightened focus on developing gene-based therapies, as these advancements boost the precision and efficacy of gene editing methods. Adeno-associated virus (AAV) vectors in gene therapy contribute to the creation of gene-based therapies by ensuring the safe and efficient delivery of therapeutic genes into target cells, thanks to their low immunogenicity and capacity for sustained gene expression. For example, data from IQVIA, a US-based provider of advanced analytics and technology solutions for the life sciences industry, indicated that global expenditure on cell and gene therapies reached $5.9 billion in 2023, marking a 38% rise compared to 2022. Consequently, the expanding focus on developing gene-based therapies is stimulating the growth of the adeno-associated virus (AAV) vectors market.

What Are The Major Segments Identified In The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

The adeno-associated virus (avv) vectors in gene therapy market covered in this report is segmented –

1) By Type of Therapy: Gene Augmentation, Immunotherapy, Other Type of Therapy

2) By Type of Gene Delivery Method Used: Ex Vivo, In Vivo

3) By Scale of Operation: Preclinical, Clinical, Commercial

4) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Area

Subsegments:

1) By Gene Augmentation: Monogenic Disorders, Neurological Disorders, Muscular Disorders, Ophthalmological Disorders, Metabolic Disorders

2) By Immunotherapy: Oncology, Infectious Diseases, Autoimmune Disorders, Vaccine Development, T-Cell Engineering

3) By Other Type of Therapy: Gene Editing Support, RNA Interference, Neuroprotection and Neuroregeneration, Anti-Inflammatory Applications, Regenerative Medicine

What Trends Are Redefining The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Dynamics?

Major companies engaged in the adeno-associated virus (AAV) vectors within the gene therapy market are concentrating on advanced innovations, notably tailored vector diversity for assay versatility. This approach aims to enhance target tissue specificity, improve therapeutic efficacy, and accelerate the development of customized gene therapies for a wide range of indications. Tailored vector diversity for assay versatility refers to the strategic use of multiple AAV serotypes or constructs to support diverse analytical tests and therapeutic applications. For instance, in May 2024, Charles River Laboratories, a US-based pharmaceutical company, introduced new reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV). These materials are intended to support the expanding requirements of cell and gene therapy (CGT) development. The comprehensive portfolio facilitates a smoother transition from early-stage research to GMP-grade production, helping to standardize processes and improve consistency in viral vector manufacturing. This launch effectively addresses a critical challenge in scaling CGT programs towards clinical and commercial readiness.

Which Leading Companies Dominate The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Share?

Major companies operating in the adeno-associated virus (AVV) vectors in gene therapy market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Astellas Gene Therapies Inc., Biogen Inc., Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/adeno-associated-virus-avv-vectors-in-gene-therapy-global-market-report

What Regional Growth Trends Are Shaping The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Outlook?

North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2024. The regions covered in the adeno-associated virus (AVV) vectors in gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24135&type=smp

Browse Through More Reports Similar to the Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market 2025, By The Business Research Company

Gene Editing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report

Nucleic Acid Based Gene Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Genes Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Present And Forecasted Size Of The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

The market size of gene therapy involving adeno-associated virus (avv) vectors has seen a quick expansion in the past few years. The market’s value is set to increase from $2.7 billion in 2024 to $3.16 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 16.7%. Factors driving this growth during the historical period include ramped up investment in gene therapy research, an increased uptake of gene editing technologies, the escalating prevalence of genetic disorders and unresolved healthcare requirements, the burgeoning demand for targeted therapies, and a rise in partnerships among biotech firms and research institutes.

Anticipated to experience significant growth in the upcoming years, the adeno-associated virus (AAV) vectors in gene therapy sector is projected to swell to $6.09 billion by 2029 with a compound annual growth rate (CAGR) of 17.6%. This growth trajectory in the predicted timeframe can be credited to factors such as the progressive developments in AAV capsid engineering, heightened focus on precision medicine, expanding investments in genetic investigation and biotechnology, an uptick in gene therapy clinical examinations and clearances, and a surge in demand for tailored treatments. Key trends to watch out for during this period include the ascension of artificial intelligence in AAV capsid engineering, creation of hybrid AAV vectors capable of handling larger genetic information, advancements in bispecific antibody-mediated AAV guidance, elevation in scalable AAV production and cleaning technology, and emergence of adaptable AAV platforms supporting an array of viral vectors.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp

What Growth-Enabling Forces Are Impacting The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

The burgeoning interest in gene-oriented treatments is forecasted to drive the expansion of the adeno-associated virus (AAV) vectors in the gene therapy market in the future. Gene-focused therapies are interventions that adjust or control genes to avert, manage, or treat ailments at the genetic level. Progress in genetic studies fuels the growing emphasis on developing gene-oriented therapies, as it improves the accuracy and efficacy of gene editing methods. Adeno-associated virus (AAV) vectors in gene therapy aid in forming gene-focused treatments by securely and efficiently transmitting healing genes into targeted cells, due to their minimal immune response and capability to sustain long-term gene expression. For instance, in 2023, IQVIA, a US-based firm offering cutting-edge analytics and technology solutions for the life sciences sector, reported that global expenditure on cell and gene therapies amounted to $5.9 billion, signifying a 38% rise from the previous year. Hence, the rising emphasis on developing gene-oriented treatments is fuelling the expansion of the adeno-associated virus (AAV) vectors market.

What Are The Main Segment Classifications In The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

The adeno-associated virus (avv) vectors in gene therapy market covered in this report is segmented –

1) By Type of Therapy: Gene Augmentation, Immunotherapy, Other Type of Therapy

2) By Type of Gene Delivery Method Used: Ex Vivo, In Vivo

3) By Scale of Operation: Preclinical, Clinical, Commercial

4) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Area

Subsegments:

1) By Gene Augmentation: Monogenic Disorders, Neurological Disorders, Muscular Disorders, Ophthalmological Disorders, Metabolic Disorders

2) By Immunotherapy: Oncology, Infectious Diseases, Autoimmune Disorders, Vaccine Development, T-Cell Engineering

3) By Other Type of Therapy: Gene Editing Support, RNA Interference, Neuroprotection and Neuroregeneration, Anti-Inflammatory Applications, Regenerative Medicine

How Are Industry Trends Steering The Expansion Of The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

Leading corporations within the adeno-associated virus (AAV) vectors realm in the gene therapy market are concentrating their efforts on progressive innovation, such as customizing vector diversity to augment assay versatility, which in turn magnifies target tissue specificity, augments therapeutic efficacy, and expedites the progression of personal gene therapies throughout diverse indications. Utilizing various AAV serotypes or structures to aid diverse analytical methods and therapeutic applications is what tailored vector diversity for assay versatility signifies. For example, Charles River Laboratories, an American pharmaceutical company, announced the release of new reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV) in May 2024. These materials cater to the escalating demands of cell and gene therapy (CGT) advancement. This provision streamlines transitioning from preliminary research to GMP-grade output, standardizing processes and refining uniformity in viral vector production. This introduction addresses a crucial obstacle in amplifying CGT programs for clinical and commercial preparedness.

Which Companies Are Contributing Significantly To The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Growth?

Major companies operating in the adeno-associated virus (AVV) vectors in gene therapy market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Astellas Gene Therapies Inc., Biogen Inc., Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/adeno-associated-virus-avv-vectors-in-gene-therapy-global-market-report

Which Region Holds The Greatest Opportunity For Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Expansion?

North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2024. The regions covered in the adeno-associated virus (AVV) vectors in gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=24135&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Present And Forecasted Size Of The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

The market size of gene therapy involving adeno-associated virus (avv) vectors has seen a quick expansion in the past few years. The market’s value is set to increase from $2.7 billion in 2024 to $3.16 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 16.7%. Factors driving this growth during the historical period include ramped up investment in gene therapy research, an increased uptake of gene editing technologies, the escalating prevalence of genetic disorders and unresolved healthcare requirements, the burgeoning demand for targeted therapies, and a rise in partnerships among biotech firms and research institutes.

Anticipated to experience significant growth in the upcoming years, the adeno-associated virus (AAV) vectors in gene therapy sector is projected to swell to $6.09 billion by 2029 with a compound annual growth rate (CAGR) of 17.6%. This growth trajectory in the predicted timeframe can be credited to factors such as the progressive developments in AAV capsid engineering, heightened focus on precision medicine, expanding investments in genetic investigation and biotechnology, an uptick in gene therapy clinical examinations and clearances, and a surge in demand for tailored treatments. Key trends to watch out for during this period include the ascension of artificial intelligence in AAV capsid engineering, creation of hybrid AAV vectors capable of handling larger genetic information, advancements in bispecific antibody-mediated AAV guidance, elevation in scalable AAV production and cleaning technology, and emergence of adaptable AAV platforms supporting an array of viral vectors.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp

What Growth-Enabling Forces Are Impacting The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

The burgeoning interest in gene-oriented treatments is forecasted to drive the expansion of the adeno-associated virus (AAV) vectors in the gene therapy market in the future. Gene-focused therapies are interventions that adjust or control genes to avert, manage, or treat ailments at the genetic level. Progress in genetic studies fuels the growing emphasis on developing gene-oriented therapies, as it improves the accuracy and efficacy of gene editing methods. Adeno-associated virus (AAV) vectors in gene therapy aid in forming gene-focused treatments by securely and efficiently transmitting healing genes into targeted cells, due to their minimal immune response and capability to sustain long-term gene expression. For instance, in 2023, IQVIA, a US-based firm offering cutting-edge analytics and technology solutions for the life sciences sector, reported that global expenditure on cell and gene therapies amounted to $5.9 billion, signifying a 38% rise from the previous year. Hence, the rising emphasis on developing gene-oriented treatments is fuelling the expansion of the adeno-associated virus (AAV) vectors market.

What Are The Main Segment Classifications In The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

The adeno-associated virus (avv) vectors in gene therapy market covered in this report is segmented –

1) By Type of Therapy: Gene Augmentation, Immunotherapy, Other Type of Therapy

2) By Type of Gene Delivery Method Used: Ex Vivo, In Vivo

3) By Scale of Operation: Preclinical, Clinical, Commercial

4) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Area

Subsegments:

1) By Gene Augmentation: Monogenic Disorders, Neurological Disorders, Muscular Disorders, Ophthalmological Disorders, Metabolic Disorders

2) By Immunotherapy: Oncology, Infectious Diseases, Autoimmune Disorders, Vaccine Development, T-Cell Engineering

3) By Other Type of Therapy: Gene Editing Support, RNA Interference, Neuroprotection and Neuroregeneration, Anti-Inflammatory Applications, Regenerative Medicine

How Are Industry Trends Steering The Expansion Of The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

Leading corporations within the adeno-associated virus (AAV) vectors realm in the gene therapy market are concentrating their efforts on progressive innovation, such as customizing vector diversity to augment assay versatility, which in turn magnifies target tissue specificity, augments therapeutic efficacy, and expedites the progression of personal gene therapies throughout diverse indications. Utilizing various AAV serotypes or structures to aid diverse analytical methods and therapeutic applications is what tailored vector diversity for assay versatility signifies. For example, Charles River Laboratories, an American pharmaceutical company, announced the release of new reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV) in May 2024. These materials cater to the escalating demands of cell and gene therapy (CGT) advancement. This provision streamlines transitioning from preliminary research to GMP-grade output, standardizing processes and refining uniformity in viral vector production. This introduction addresses a crucial obstacle in amplifying CGT programs for clinical and commercial preparedness.

Which Companies Are Contributing Significantly To The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Growth?

Major companies operating in the adeno-associated virus (AVV) vectors in gene therapy market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Astellas Gene Therapies Inc., Biogen Inc., Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/adeno-associated-virus-avv-vectors-in-gene-therapy-global-market-report

Which Region Holds The Greatest Opportunity For Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Expansion?

North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2024. The regions covered in the adeno-associated virus (AVV) vectors in gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=24135&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Size Shifted, And What Is the Outlook Through 2034?

The market size for adeno-associated virus (avv) vectors utilized in gene therapy has experienced swift expansion lately, with projections showing it escalating from $2.7 billion in 2024 to a substantial $3.16 billion in 2025, indicating a compound annual growth rate (CAGR) of 16.7%. This robust growth in the historical period can be credited to factors such as heightened investment in gene therapy studies, increasing embracement of gene editing technologies, amplified cases of genetic disorders and unfulfilled medical requirements, growing demand for targeted treatment approaches, and heightened cooperative efforts among biotech enterprises and academic research institutions.

Expectations for the Adeno-associated virus (AVV) vectors in gene therapy market predict a significant expansion in the coming years. It is forecasted to reach $6.09 billion by 2029, with a compound annual growth rate (CAGR) of 17.6%. The predicted expansion in this period can be ascribed to several factors like the continual advancements in AAV capsid engineering, an increased emphasis on precision medicine, escalating investments in genetic research and biotechnology, rising number of gene therapy clinical trials and approvals, and a higher demand for personalized treatments. Key trends projected to shape this period include the evolution of artificial intelligence in AAV capsid engineering, the creation of hybrid AAV vectors for larger genetic payloads, breakthroughs in bispecific antibody-mediated AAV targeting, progress in scalable AAV production and purification technologies, and the establishment of versatile AAV platforms that aid a range of viral vectors.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp

What External and Internal Drivers Are Contributing to the Growth of theAdeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

The growing emphasis on gene-oriented therapies is anticipated to stimulate the expansion of the adeno-associated virus (AAV) vectors within the gene therapy market. Gene-oriented therapies are targeted interventions that alter or intervene with genes to either prevent, manage, or entirely cure diseases on a molecular level. The surge in genetic research advancements highlights the intensifying focus on devising gene-oriented therapies because they improve the accuracy and efficacy of gene editing techniques. Adeno-associated virus (AAV) vectors used in gene therapy facilitate the construction of gene-oriented therapies by effectively and securely transporting therapeutic genes into the target cells, all thanks to their limited immunogenicity and their capacity to guarantee long-term gene expression. For example, IQVIA, a US-based company that offers enhanced analytics and technology solutions for the life science sector, reported that in 2023, worldwide expenditure on cell and gene therapies hit $5.9 billion, denoting a 38% upsurge from 2022. Therefore, the escalating emphasis on devising gene-oriented therapies is fostering the expansion of the adeno-associated virus (AAV) vectors market.

What Segment Types Define the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Structure?

The adeno-associated virus (avv) vectors in gene therapy market covered in this report is segmented –

1) By Type of Therapy: Gene Augmentation, Immunotherapy, Other Type of Therapy

2) By Type of Gene Delivery Method Used: Ex Vivo, In Vivo

3) By Scale of Operation: Preclinical, Clinical, Commercial

4) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Area

Subsegments:

1) By Gene Augmentation: Monogenic Disorders, Neurological Disorders, Muscular Disorders, Ophthalmological Disorders, Metabolic Disorders

2) By Immunotherapy: Oncology, Infectious Diseases, Autoimmune Disorders, Vaccine Development, T-Cell Engineering

3) By Other Type of Therapy: Gene Editing Support, RNA Interference, Neuroprotection and Neuroregeneration, Anti-Inflammatory Applications, Regenerative Medicine

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=24135&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2024. The regions covered in the adeno-associated virus (AVV) vectors in gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

Leading corporations in the adeno-associated virus (AAV) vectors sector of gene therapy are prioritizing innovative advancements. This includes pioneering tailored vector diversity to promote assay versatility, with the aim of improving targeted tissue precision, boosting therapeutic efficacy, and hastening the creation of customized gene therapies across various indications. Tailored vector diversity for assay versatility implies employing a range of AAV serotypes or structures to support numerous analytical tests and therapeutic uses. For example, Charles River Laboratories, an American pharmaceutical company, released new reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV) in May 2024. These materials are designed to meet the expanding demands of cell and gene therapy (CGT) development. This portfolio eases the transition from initial research to GMP-grade manufacturing and aids in standardizing procedures while enhancing consistency in viral vector production. This launch targets a prevalent hurdle in escalating CGT programs towards clinical and commercial readiness.

View the full report here:

https://www.thebusinessresearchcompany.com/report/adeno-associated-virus-avv-vectors-in-gene-therapy-global-market-report

What Is the Definition of the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

Adeno-associated virus (AAV) vectors in gene therapy are advanced delivery tools that transport genetic material into cells to treat various genetic disorders. Their primary goal is to enable targeted, long-lasting therapeutic effects by correcting or modifying faulty genes. AAV vectors are valued for their safety, low immunogenicity, and ability to deliver genes to both dividing and non-dividing cells, supporting the development of precise and durable gene therapies that advance personalized medicine and transform the treatment of rare and inherited diseases.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24135

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model